Patient demographics and transplant characteristics
| Factor . | Fluconazole (n = 152) . | Placebo (n = 148) . | P . |
|---|---|---|---|
| Mean age, years (range) | 36.4 (13, 60) | 36.1 (11, 65) | .80 |
| Gender | |||
| Male | 85 | 89 | .46 |
| Female | 67 | 59 | |
| Underlying disease | .06 | ||
| Acute lymphocytic leukemia | 9 | 22 | |
| Acute nonlymphocytic leukemia | 35 | 24 | |
| Chronic lymphocytic leukemia | 62 | 50 | |
| Hodgkin lymphoma | 7 | 13 | |
| Non-Hodgkin lymphoma | 18 | 16 | |
| Other | 21 | 23 | |
| Transplant type | .99 | ||
| Autologous | 18 | 17 | |
| HLA matched allogeneic | 78 | 76 | |
| HLA mismatched or unrelated allogeneic | 56 | 55 | |
| Transplant in LAF | .51 | ||
| Yes | 52 | 56 | |
| No | 100 | 92 | |
| Conditioning regimen | |||
| BU + CY | 24 | 32 | |
| BCNU, CY, VP-16 | 13 | 16 | |
| CY + TBI (≤1200 cGy) | 52 | 38 | |
| CY + TBI (>1200 cGy) | 61 | 59 | .43 |
| Other | 2 | 3 | |
| GVHD prophylaxis* | .518 | ||
| Cyclosporin A | 21 | 26 | |
| Cyclosporin A and methotrexate | 101 | 95 | |
| Methotrexate | 6 | 8 | |
| Other | 5 | 2 | |
| Marrow cell dose: mean (range) | 192 (23, 641) | 199 (58, 656) | .51 |
| Recipient CMV serology | |||
| Positive | 62 | 56 | .60 |
| Negative | 90 | 92 |
| Factor . | Fluconazole (n = 152) . | Placebo (n = 148) . | P . |
|---|---|---|---|
| Mean age, years (range) | 36.4 (13, 60) | 36.1 (11, 65) | .80 |
| Gender | |||
| Male | 85 | 89 | .46 |
| Female | 67 | 59 | |
| Underlying disease | .06 | ||
| Acute lymphocytic leukemia | 9 | 22 | |
| Acute nonlymphocytic leukemia | 35 | 24 | |
| Chronic lymphocytic leukemia | 62 | 50 | |
| Hodgkin lymphoma | 7 | 13 | |
| Non-Hodgkin lymphoma | 18 | 16 | |
| Other | 21 | 23 | |
| Transplant type | .99 | ||
| Autologous | 18 | 17 | |
| HLA matched allogeneic | 78 | 76 | |
| HLA mismatched or unrelated allogeneic | 56 | 55 | |
| Transplant in LAF | .51 | ||
| Yes | 52 | 56 | |
| No | 100 | 92 | |
| Conditioning regimen | |||
| BU + CY | 24 | 32 | |
| BCNU, CY, VP-16 | 13 | 16 | |
| CY + TBI (≤1200 cGy) | 52 | 38 | |
| CY + TBI (>1200 cGy) | 61 | 59 | .43 |
| Other | 2 | 3 | |
| GVHD prophylaxis* | .518 | ||
| Cyclosporin A | 21 | 26 | |
| Cyclosporin A and methotrexate | 101 | 95 | |
| Methotrexate | 6 | 8 | |
| Other | 5 | 2 | |
| Marrow cell dose: mean (range) | 192 (23, 641) | 199 (58, 656) | .51 |
| Recipient CMV serology | |||
| Positive | 62 | 56 | .60 |
| Negative | 90 | 92 |
Data from original study reproduced with permission of editor.18 Note small differences in numbers occurred as a result of updating of computerized database and correction of typographical error.
BU indicates busulfan; CY, cyclophosphamide; BCNU, bischloroethylnitrosourea; TBI, total body irradiation; GVHD, graft-versus-host disease; CMV, cytomegalovirus.
GVHD prophylaxis for allogeneic patients. No data was available for one fluconazole recipient.